Kura Oncology, Inc. (KURA) Reports Preclinical KO-7246 Data Showing β-Cell Regeneration

Kura Oncology reported preclinical data for KO-7246, a selective menin inhibitor that regenerated β-cell mass and improved glycemic control in T1D and T2D models, with human islet activity, and said IND-enabling development is underway.Material DetailsContext by AI AnalystThis is early-stage, precl…